Health News (Reuters)

Roche CEO says new drugs will offset biosimilar incursions

ZURICH (Reuters) - Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals' copies through its new medicines, Chief Executive Severin Schwan said on Tuesday.

EBRD issues its first 'health bond' worth 317 million zlotys

WARSAW/LONDON (Reuters) - The European Bank for Reconstruction and Development (EBRD) said on Tuesday it has issued its first "health bond", raising 317 million zlotys ($92.84 million) from one of Japan's largest life insurers to finance health projects across the globe.

USDA withdraws proposal to stiffen rules for organic egg farms

CHICAGO (Reuters) - The U.S. Department of Agriculture scrapped proposed rules on Monday that for the first time would have mandated specific space requirements for hens laying organic eggs and spelled out what it means for the birds to have access to the outdoors.

Judge rejects Massachusetts challenge to Trump birth control rules

BOSTON (Reuters) - A federal judge on Monday rejected a lawsuit by Massachusetts' attorney general challenging new rules by President Donald Trump's administration that make it easier for employers to avoid providing insurance that covers women's birth control.

Impax broke U.S. antitrust law by delaying generic drug, jury told

BOSTON (Reuters) - Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer.

Europe's drinks sector tells EU it will offer more product info

BRUSSELS (Reuters) - Europe's drinks sector announced plans on Monday to inform consumers more about the energy content and ingredients in beer, wine and spirits in a self-policing move, but critics said much of this information would only be available online.

Newer gout drug poses risk to heart patients

Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded

Mexico reports two outbreaks of highly pathogenic H7N3 bird flu: OIE

PARIS (Reuters) - Mexico reported two outbreaks of highly pathogenic H7N3 bird flu virus in the central part of the country, of which one at chicken farm, the World Organisation for Animal Health said on Monday, citing a Mexican agriculture ministry report.

Impax faces U.S. antitrust trial over generic acne drug's delay

BOSTON (Reuters) - Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer.

GSK wins new reprieve as Hikma's generic Advair delayed again

(Reuters) - GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.

Hikma plans new clinical study over generic Advair

(Reuters) - Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.

How infertility treatment has left sperm science behind

LONDON, (Reuters) – - They can make test-tube babies, grow human eggs in a lab and reproduce mice from frozen testicle tissue, but when it comes to knowing how a man's sperm can swim to, find and fertilize an egg, scientists are still floundering.

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

(Reuters) - A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.